{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T18:08:16Z","timestamp":1789236496465,"version":"build-2803163510"},"reference-count":42,"publisher":"Hindawi Limited","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Pharm Ther"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1111\/jcpt.12361","type":"journal-article","created":{"date-parts":[[2016,2,6]],"date-time":"2016-02-06T07:34:31Z","timestamp":1454744071000},"page":"111-115","source":"Crossref","is-referenced-by-count":8,"title":["Antihypertensive therapy for the prevention of nephropathy in diabetic hypertensive patients"],"prefix":"10.1155","volume":"41","author":[{"given":"A. N.","family":"Isaacs","sequence":"first","affiliation":[{"name":"Purdue University College of Pharmacy; Department of Pharmacy Practice; West Lafayette IN USA"},{"name":"Eskenazi Health; Department of Pharmacy Services; Indianapolis IN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Vincent","sequence":"additional","affiliation":[{"name":"Purdue University College of Pharmacy; Department of Pharmacy Practice; West Lafayette IN USA"},{"name":"Indiana University Health; Methodist Hospital, Department of Pharmacy; Indianapolis IN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"98","published-online":{"date-parts":[[2016,2,6]]},"reference":[{"key":"10.1111\/jcpt.12361-BIB0001|jcpt12361-cit-0001","unstructured":"National Diabetes Statistics Report 2014 CDC National Center for Chronic Disease Prevention and Health Promotion: Division of Diabetes Translation http:\/\/www.cdc.gov\/diabetes\/pubs\/statsreport14\/national-diabetes-report-web.pdf"},{"key":"10.1111\/jcpt.12361-BIB0002|jcpt12361-cit-0002","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.2337\/dc15-S011","article-title":"Standards of medical care in diabetes 2015","volume":"38","author":"American Diabetes Association","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1111\/jcpt.12361-BIB0003|jcpt12361-cit-0003","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 evidence-based guidelines for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)","volume":"311","author":"James","year":"2014","journal-title":"JAMA"},{"key":"10.1111\/jcpt.12361-BIB0004|jcpt12361-cit-0004","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)","volume":"288","author":"The ALLHAT Collaborative Research Group","year":"2002","journal-title":"JAMA"},{"key":"10.1111\/jcpt.12361-BIB0005|jcpt12361-cit-0005","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1136\/bmj.317.7160.703","article-title":"Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38","volume":"317","author":"UK Prospective Diabetes Study Group","year":"1998","journal-title":"BMJ"},{"key":"10.1111\/jcpt.12361-BIB0006|jcpt12361-cit-0006","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2337\/dc12-0755","article-title":"Generic medications and blood pressure control in diabetic hypertensive subjects","volume":"36","author":"Cummings","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1111\/jcpt.12361-BIB0007|jcpt12361-cit-0007","doi-asserted-by":"crossref","first-page":"164","DOI":"10.2337\/diacare.28.1.164","article-title":"Diabetic nephropathy: diagnosis, prevention, and treatment","volume":"28","author":"Gross","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1111\/jcpt.12361-BIB0008|jcpt12361-cit-0008","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","author":"The Diabetes Control and Complications Trial Research Group","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12361-BIB0009|jcpt12361-cit-0009","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes: UKPDS 33","volume":"352","author":"UK Prospective Diabetes Study Group","year":"1998","journal-title":"Lancet"},{"key":"10.1111\/jcpt.12361-BIB0010|jcpt12361-cit-0010","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","article-title":"Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principle results of the hypertension optimal trial (HOT) randomized trial","volume":"351","author":"Hansson","year":"1998","journal-title":"Lancet"},{"key":"10.1111\/jcpt.12361-BIB0011|jcpt12361-cit-0011","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.2337\/diacare.25.2007.S85","article-title":"Diabetic nephropathy","volume":"25","author":"American Diabetes Association","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1111\/jcpt.12361-BIB0012|jcpt12361-cit-0012","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.2337\/diacare.27.2007.S79","article-title":"Nephropathy in diabetes","volume":"27","author":"American Diabetes Association","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1111\/jcpt.12361-BIB0013|jcpt12361-cit-0013","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.2337\/diacare.26.7.2150","article-title":"Progression to overt nephropathy in type 2 diabetes: The Casale Monferrato Study","volume":"26","author":"Bruno","year":"2003","journal-title":"Diabetes Care"},{"issue":"S2","key":"10.1111\/jcpt.12361-BIB0014|jcpt12361-cit-0014","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1053\/j.ajkd.2012.12.016","article-title":"Risk factors for ESRD in individuals with preserved estimated GFR with and without albuminuria: results from the kidney early evaluation program (KEEP)","volume":"61","author":"Chang","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"10.1111\/jcpt.12361-BIB0015|jcpt12361-cit-0015","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.1001\/jama.289.24.3273","article-title":"Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus","volume":"289","author":"Kramer","year":"2003","journal-title":"JAMA"},{"key":"10.1111\/jcpt.12361-BIB0016|jcpt12361-cit-0016","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/nep.12446","article-title":"Albuminuria and reduced glomerular filtration rate for predicting the renal outcomes in type 2 diabetic patients","volume":"20","author":"Tanaka","year":"2015","journal-title":"Nephrology"},{"key":"10.1111\/jcpt.12361-BIB0017|jcpt12361-cit-0017","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1016\/j.jacc.2004.09.006","article-title":"Reduced glomerular filtration rate in asymptomatic diabetic patients: predictor of increased risk for cardiac events independent of albuminuria","volume":"44","author":"Knobler","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/jcpt.12361-BIB0018|jcpt12361-cit-0018","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/MNH.0b013e3283293db1","article-title":"Early nephropathy in type 1 diabetes: the importance of early reanl function decline","volume":"18","author":"Perkins","year":"2009","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1111\/jcpt.12361-BIB0019|jcpt12361-cit-0019","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.2337\/dc12-2572","article-title":"Renal structure in normoalbuminuric and albuminuric patients with type 2 diabetes and impaired renal function","volume":"36","author":"Ekinci","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1111\/jcpt.12361-BIB0020|jcpt12361-cit-0020","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy: the Collaborative Study Group","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12361-BIB0021|jcpt12361-cit-0021","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12361-BIB0022|jcpt12361-cit-0022","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12361-BIB0023|jcpt12361-cit-0023","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12361-BIB0024|jcpt12361-cit-0024","doi-asserted-by":"crossref","first-page":"370","DOI":"10.7326\/0003-4819-134-5-200103060-00009","article-title":"Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin converting enzyme inhibitors? A meta-analysis of individual patient data","volume":"134","author":"The ACE Inhibitors in Diabetic Nephropathy Trialist Group","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1111\/jcpt.12361-BIB0025|jcpt12361-cit-0025","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1161\/01.CIR.0000024416.33113.0A","article-title":"Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus","volume":"106","author":"Viberti","year":"2002","journal-title":"Circulation"},{"key":"10.1111\/jcpt.12361-BIB0026|jcpt12361-cit-0026","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/jch.12237","article-title":"Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and International Society of Hypertension","volume":"16","author":"Weber","year":"2014","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1111\/jcpt.12361-BIB0027|jcpt12361-cit-0027","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1093\/eurheartj\/eht151","article-title":"2013 ESH\/ESC guidelines for the management of arterial hypertension","volume":"34","author":"Mancia","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1111\/jcpt.12361-BIB0028|jcpt12361-cit-0028","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1161\/CIRCULATIONAHA.107.183885","article-title":"Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention","volume":"115","author":"Rosendorff","year":"2007","journal-title":"Circulation"},{"key":"10.1111\/jcpt.12361-BIB0029|jcpt12361-cit-0029","first-page":"193","article-title":"American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of hypertension","volume":"12","author":"Torre","year":"2006","journal-title":"Endocr Pract"},{"key":"10.1111\/jcpt.12361-BIB0030|jcpt12361-cit-0030","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease","volume":"43","author":"Levey","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1111\/jcpt.12361-BIB0031|jcpt12361-cit-0031","volume-title":"Goodman & Gilman's manual of pharmacology and therapeutics","author":"Brunton","year":"2008"},{"key":"10.1111\/jcpt.12361-BIB0032|jcpt12361-cit-0032","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jdiacomp.2006.06.001","article-title":"Renoprotective effect of N-type Ca channel blockade in diabetic nephropathy","volume":"21","author":"Fujisawa","year":"2007","journal-title":"J Diabetes Complications"},{"key":"10.1111\/jcpt.12361-BIB0033|jcpt12361-cit-0033","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined angiotensin inhibition for the treatment of diabetic nephropathy","volume":"368","author":"Fried","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12361-BIB0034|jcpt12361-cit-0034","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s11892-013-0391-y","article-title":"Combined use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in diabetic nephropathy","volume":"13","author":"Staton","year":"2013","journal-title":"Curr Diab Rep"},{"key":"10.1111\/jcpt.12361-BIB0035|jcpt12361-cit-0035","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1177\/2042098615589905","article-title":"Combination use of medicines from two classes of renin-angiotensin system blocking agents: risk of hyperkalemia, hypotension, and impaired renal function","volume":"6","author":"Esteras","year":"2015","journal-title":"Ther Adv Drug Saf"},{"key":"10.1111\/jcpt.12361-BIB0036|jcpt12361-cit-0036","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/S0140-6736(96)10244-0","article-title":"Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria","volume":"349","author":"EUCLID study group","year":"1997","journal-title":"Lancet"},{"key":"10.1111\/jcpt.12361-BIB0037|jcpt12361-cit-0037","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1136\/bmj.305.6860.981","article-title":"Comparison of enalapril and nifedipine in treating non-insulin dependent diabetes associated with hypertension: one year analysis","volume":"305","author":"Chan","year":"1992","journal-title":"BMJ"},{"issue":"S2","key":"10.1111\/jcpt.12361-BIB0038|jcpt12361-cit-0038","first-page":"B54","article-title":"Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes","volume":"23","author":"Estacio","year":"2000","journal-title":"Diabetes Care"},{"key":"10.1111\/jcpt.12361-BIB0039|jcpt12361-cit-0039","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0168-8227(01)00288-1","article-title":"Nifedipine and enalapril equally reduce the progression of nephropathy in hypertensive type 2 diabetics","volume":"54","author":"Baba","year":"2001","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1111\/jcpt.12361-BIB0040|jcpt12361-cit-0040","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1056\/NEJMoa1007994","article-title":"Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes","volume":"364","author":"Haller","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12361-BIB0041|jcpt12361-cit-0041","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa042167","article-title":"Preventing microalbuminuria in type 2 diabetes","volume":"351","author":"Ruggenenti","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12361-BIB0042|jcpt12361-cit-0042","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","article-title":"The seventh report of the Joint National Committee on Prevention, Detection, and Treatment of High Blood Pressure: the JNC 7 report","volume":"289","author":"Chobanian","year":"2003","journal-title":"JAMA"}],"container-title":["Journal of Clinical Pharmacy and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjcpt.12361","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjcpt.12361","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jcpt.12361\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T18:06:15Z","timestamp":1671818775000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jcpt.12361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,6]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,4]]}},"URL":"https:\/\/doi.org\/10.1111\/jcpt.12361","archive":["Portico"],"relation":{},"ISSN":["0269-4727"],"issn-type":[{"value":"0269-4727","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2,6]]}}}